Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pozen to file NSAID/PPI combo

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pozen will file the NDA for the NSAID/PPI combination product PN 400 in mid-2009, the firm announced May 13. With partner AstraZeneca, Pozen developed the fixed-dose combination of the NSAID naproxen with the PPI esomeprazole to treat the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who are at risk of developing gastric ulcers (1"The Pink Sheet" DAILY, Aug. 2, 2006). Pozen's announcement suggests that FDA has resolved its concerns about the appropriateness of reduction in gastric ulcers as an endpoint for approval of a gastroprotective claim for NSAID/PPI combos (2"Pharmaceutical Approvals Monthly," December 2008, p. 34)

You may also be interested in...



FDA Raising Approval Bar For NSAID/PPI Combos; Endpoints Under Review

FDA is considering changes to the approval process for NSAID and proton pump inhibitor combination products that may result in the agency prohibiting the use of endoscopic gastric ulcer reduction to support a gastroprotective marketing claim

AstraZeneca, Pozen To Partner On Fixed-Dose Naproxen/Esomeprazole

AstraZeneca will oversee global manufacturing, marketing, sales and distribution for the arthritis pain compound.

EMA Endorses Dexamethasone For COVID-19

Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel